Abstract 70P
Background
NSCLC treatment has evolved after approval of the 1st immunotherapy agent (IO) in 2015. The real-world LIST study of nivolumab for advanced NSCLC aims to describe patient/treatment characteristics, effectiveness, safety and rechallenge outcomes.
Methods
LIST is an ongoing longitudinal, prospective, observational study in patients (pts) with advanced NSCLC receiving nivolumab after one prior chemotherapy-based treatment alone or in combination with IO. Patient cohorts were: Cohort 1, IO-naïve patients; Cohort 2, IO-experienced patients who discontinued for non-IO-toxicity reasons; Cohort 3, IO-experienced patients who discontinued due to IO-toxicity. Descriptive interim analyses (follow-up ≥6 months) are presented.
Results
428 pts were enrolled between Sept 2020 and May 2022 at 99 centres – 278, 128 and 22 pts in cohorts 1, 2 and 3. Baseline patient characteristics were representative of advanced NSCLC: median age 65–70 years, male sex >65%, current/former smoker 22–27%/65–73%, non-squamous histology 60–75%. 41%/ 71%/ 76% of pts in cohorts 1/2/3 had PD-L1 expression (≥1%). At 6 months, respective overall survival (OS) rates were 70.0% [95% confidence interval 64.2–75.1%]/ 61.1% [51.6–69.3%]/ 61.2% [37.1–78.4%] and progression-free survival (PFS) were 33.4% [27.6–39.2%]/ 25.1% [17.2–33.8%]/ 51.0% [28.1–70.0%]. Current/former smokers and pts with tumour PD-L1 expression seem to have improved outcomes (table). All adverse events (AEs) occurred in 86%/ 78%/ 73% of pts and treatment-related grade 3/4 AEs in 11%/ 5%/ 18%, in cohorts 1/ 2/ 3. Table: 70P
Interim survival data by cohort and smoking and PD-L1 status
Cohort 1 (n=278) | Cohort 2 (n=127) | Cohort 3 (n=22) | ||||
Median, months | Rate at 6 months, % | Median, months | Rate at 6 months, % | Median, months | Rate at 6 months, % | |
OS | ||||||
Overall | 12.2 | 70.0 | 8.3 | 61.1 | 10.4 | 61.2 |
Never smoker | 8.1 | 62.9 | 9.5 | 77.8 | – | – |
Former smoker | 12.2 | 72.4 | 6.7 | 54.6 | 10.4 | 58.7 |
Current smoker | 12.6 | 66.5 | 11.0 | 76.0 | – | – |
PD-L1 <1% | – | – | – | – | – | – |
PD-L1 1–49% | 12.2 | 63.6 | 6.7 | 53.5 | – | – |
PD-L1 ≥50% | 7.3 | 61.1 | 9.6 | 60.7 | – | – |
PFS | ||||||
Overall | 3.2 | 33.4 | 2.9 | 25.1 | 7.6 | 51.0 |
Never smoker | 3.0 | 24.0 | – | – | - | - |
Former smoker | 3.9 | 35.6 | 2.2 | 20.6 | 3.2 | 46.7 |
Current smoker | 2.7 | 30.9 | 3.9 | 36.6 | – | – |
PD-L1 <1% | – | – | – | – | – | – |
PD-L1 1–49% | 3.5 | 42.3 | 2.2 | 16.0 | – | – |
PD-L1 ≥50% | 1.8 | 16.7 | 2.1 | 24.8 | – | – |
– = n<15 |
Conclusions
LIST interim results show nivolumab for IO-naïve pts in clinical practice has similar activity and safety as in the registrational CheckMate 017/057 trials. It shows encouraging results of rechallenge with nivolumab in pts with previous IO discontinuation, including for IO-toxicity.
Clinical trial identification
NCT04500535.
Editorial acknowledgement
We thank Sheridan Henness who provided medical writing assistance prior to submission on behalf of Springer Healthcare Communications.
Legal entity responsible for the study
The authors.
Funding
Bristol Myers Squibb.
Disclosure
B. Godbert: Financial Interests, Personal, Speaker, Consultant, Advisor: Bristol Myers Squibb, AstraZeneca, Sanofi, MSD; Financial Interests, Personal, Advisory Board: Bristol Myers Squibb, AstraZeneca, MSD, Sanofi; Financial Interests, Personal, Expert Testimony: Bristol Myers Squibb, AstraZeneca, Sanofi, MSD. M. Zysman: Financial Interests, Institutional, Other: AVAD; Financial Interests, Personal, Speaker, Consultant, Advisor: CSL Behring, GSK, Boehringer Ingelheim, AstraZeneca, Chiesi, Sanofi; Financial Interests, Personal, Other: Chiesi, AstraZeneca, GSK. E. Gobbini: Financial Interests, Institutional, Other: BMS; Financial Interests, Personal, Other: AstraZeneca, Roche, Pfizer, Merck Sharpe and Dohm, Bristol Myers Squibb, Takeda, Janssen, Sanofi. C. Decroisette: Financial Interests, Personal, Speaker, Consultant, Advisor: MSD, BMS, Takeda, Pfizer, Sanofi, Janssen, AstraZeneca, Amgen; Financial Interests, Personal, Other: Amgen, Janssen, Roche, MSD. H. Lena: Financial Interests, Personal, Speaker, Consultant, Advisor: Roche AstraZeneca, MSD, Novartis, Takeda, BMS, Roche, MSD, Pfizer, Lilly, Amgen; Financial Interests, Personal, Other: BMS, Takeda, Pfizer. D. Moro-Sibilot: Financial Interests, Personal, Speaker, Consultant, Advisor: BMS, MSD, Roche, AstraZeneca; Financial Interests, Personal, Other: Roche, MSD; Financial Interests, Personal, Advisory Board: BMS, Roche, MSD; Financial Interests, Institutional, Other: BMS, Roche, MSD. F. Guisier: Financial Interests, Personal, Advisory Board: Amgen, AstraZeneca, BMS, MSD, Roche, Sanofi, Janssen, Pfizer, Takeda; Financial Interests, Institutional, Research Grant: Pfizer, Roche, Takeda. S. Couraud: Other, Personal, Advisory Board: Adene; Financial Interests, Personal and Institutional, Advisory Board, Institution Funding: Amgen, BMS, MSD, Novartis, Pfizer, Sanofi; Financial Interests, Personal and Institutional, Advisory Board, Institution Funding, Research Funding: AstraZeneca; Financial Interests, Institutional, Research Funding: BD, Transdiag, Volition; Financial Interests, Institutional, Funding: Celgene, Chugai, Janssen, Laidet, Lilly, Roche, Takeda; Financial Interests, Personal, Speaker, Consultant, Advisor: Health EvenT; Financial Interests, Personal, Advisory Board: MaaT Pharma. A. Caraux: Financial Interests, Personal, Affiliate: Bristol Myers Squibb. D. Reynaud: Financial Interests, Personal Boehringer Ingelheim, Affiliate: Bristol Myers Squibb. F. Breliier: Financial Interests, Personal, Affiliate: Bristol Myers Squibb; Financial Interests, Personal, Stocks or ownership: Bristol Myers Squibb. N. Girard: Financial Interests, Personal, Invited Speaker: AstraZeneca, BMS, MSD, Roche, Pfizer, Mirati, Amgen, Novartis, Sanofi, Gilead; Financial Interests, Personal, Advisory Board: AstraZeneca, BMS, MSD, Roche, Pfizer, Janssen, Boehringer Ingelheim, Novartis, Sanofi, AbbVie, Amgen, Lilly, Grunenthal, Takeda, Owkin, Leo Pharma, Daiichi Sankyo, Ipsen; Financial Interests, Institutional, Research Grant, Local: Roche, Sivan, Janssen; Financial Interests, Institutional, Funding: BMS, Leo Pharma; Financial Interests, Institutional, Research Grant: MSD; Non-Financial Interests, Personal, Officer, International Thymic malignancy interest group, president: ITMIG; Other, Personal, Other, Family member is an employee: AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
137P - First-in-human results from a Phase I dose-escalation study of VSV-GP (BI 1831169) in patients with advanced solid tumors
Presenter: Stephane Champiat
Session: Poster Display
138P - Generation of frameshift mutated TGF_R2-specific T cells in healthy subjects following administration with cancer vaccine candidate FMPV-1/GM-CSF
Presenter: Else Inderberg
Session: Poster Display
139P - Safety and clinical activity of a novel anti-CCR8 antibody (LM-108) as a single agent or in combination with pembrolizumab in patients with advanced solid tumors: Results of phase 1 study
Presenter: Alexander Starodub
Session: Poster Display
140P - Eliciting mAbs targeting MHC-bound peptides with a novel antibody discovery platform
Presenter: Elli Sandberg
Session: Poster Display
141P - An IgE antibody targeting the melanoma-associated Chondroitin Sulfate Proteoglycan 4
Presenter: Lais Cristina Palhares
Session: Poster Display
142P - Identifying novel immunotherapy targets using machine learning and ex vivo validation
Presenter: Marcellus Augustine
Session: Poster Display
143P - Advancing Cancer Immunotherapy via HLA-G Pathway Modulation with UCB4594
Presenter: Ann WHITE
Session: Poster Display
144P - Discovery of CBO421, a first-in-class Drug Fc-Conjugate (DFC), targeting CD73 in Cancer
Presenter: Simon Döhrmann
Session: Poster Display
145P - An Engineered Ligand-Trap Biologic Targeting the CD47 Signaling Pathway for Cancer Treatment with Superb Efficacy and Safety Profiles
Presenter: ZONG SEAN JUO
Session: Poster Display
146P - A Novel Allosteric Oral Immunotherapy Small Molecule Modulates Adenosine 2A Receptor Signaling and Restores Anti-Tumor Immune Responses
Presenter: David Pejoski
Session: Poster Display